The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 3, 2013, Pages 356-363

  Mueller, Wolfgang Peter ^a   Melzer, Henriette Ingrid ^a   Schmid, Irene ^a   Coppenrath, Eva ^a   Bartenstein, Peter ^a   Pfluger, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Histiocytosis; MR PET; Paediatric oncology; PET MRI

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BONE LESION; BONE MARROW EDEMA; CANCER CHEMOTHERAPY; CELL INFILTRATION; CHILD; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTIOCYTE; HISTIOCYTOSIS; HISTOLOGY; HUMAN; INFANT; LYMPHOID TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SKULL; RETROSPECTIVE STUDY; SCINTISCANNING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HISTIOCYTOSIS; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; YOUNG ADULT;

MLCS; MLOWN;

EID: 84873993704     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2278-6     Document Type: Article

References (26)

1. Hoover KB, Rosenthal DI, Mankin H. Langerhans cell histiocytosis. Skeletal Radiol. 2007;36:95-104.
2. Grois N, Potschger U, Prosch H, Minkov M, Arico M, Braier J, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46:228-33.
3. Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol. 2002;39:581-5.
4. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001;138:728-34.
5. Schmidt S, Eich G, Geoffray A, Hanquinet S, Waibel P, Wolf R, et al. Extraosseous langerhans cell histiocytosis in children. Radiographics. 2008;28:707-26.
6. Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009;52:97-101.
7. Binkovitz LA, Olshefski RS, Adler BH. Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings. Pediatr Radiol. 2003;33:598-602.
8. Meyer JS, De Camargo B. The role of radiology in the diagnosis and follow-up of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:307-26.
9. Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2005;35:103-15.
10. Pavlik M, Bloom DA, Ozgonenel B, Sarnaik SA. Defining the role of magnetic resonance imaging in unifocal bone lesions of langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2005;27:432-5.
11. Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156:873-81.
12. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, et al. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:BP115-24.
13. Kaste SC, Rodriguez-Galindo C, McCarville ME, Shulkin BL. PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Radiol. 2007;37:615-22.
14. Blum R, Seymour JF, Hicks RJ. Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma. 2002;43:2155-7.
15. Lee HJ, Ahn BC, Lee SW, Lee J. The usefulness of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with Langerhans cell histiocytosis. Ann Nucl Med. 2012. doi: 10.1007/s12149-012-0635-y
16. Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556-62.
17. Buchler T, Cervinek L, Belohlavek O, Kantorova I, Mechl M, Nebesky T, et al. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer. 2005;44:286-8.
18. Krajicek BJ, Ryu JH, Hartman TE, Lowe VJ, Vassallo R. Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest. 2009;135:1542-9.
19. Szturz P, Rehak Z, Koukalova R, Adam Z, Krejci M, Pour L, et al. Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma. Nucl Med Biol. 2012;39:429-36.
20. Mentzel HJ, Kentouche K, Sauner D, Fleischmann C, Vogt S, Gottschild D, et al. Comparison of whole-body STIR-MRI and 99mTc-methylene-diphosphonate scintigraphy in children with suspected multifocal bone lesions. Eur Radiol. 2004;14:2297-302.
21. Goo HW, Yang DH, Ra YS, Song JS, Im HJ, Seo JJ, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol. 2006;36:1019-31.
22. Kilborn TN, Teh J, Goodman TR. Paediatric manifestations of Langerhans cell histiocytosis: a review of the clinical and radiological findings. Clin Radiol. 2003;58:269-78.
23. Kellenberger CJ, Epelman M, Miller SF, Babyn PS. Fast STIR whole-body MR imaging in children. Radiographics. 2004;24:1317-30.
24. Grois N, Tsunematsu Y, Barkovich AJ, Favara BE. Central nervous system disease in Langerhans cell histiocytosis. Br J Cancer Suppl. 1994;23:S24-8.
25. Ohno Y, Koyama H, Yoshikawa T, Nishio M, Matsumoto S, Iwasawa T, et al. Pulmonary magnetic resonance imaging for airway diseases. J Thorac Imaging. 2011;26:301-16.
26. Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-55.